share_log

Berenberg Initiates Coverage On Blueprint Medicines With Buy Rating, Announces Price Target of $90

Berenberg Initiates Coverage On Blueprint Medicines With Buy Rating, Announces Price Target of $90

贝伦伯格以买入评级启动蓝图药品保险,宣布目标价为90美元
Benzinga Real-time News ·  2022/09/14 06:46

Berenberg analyst Zhiqiang Shu initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating and announces Price Target of $90.

贝伦伯格分析师舒志强以买入评级开始对蓝图药品(纳斯达克股票代码:BPMC)进行报道,并宣布目标股价为90美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发